Novo projects flat 2026 sales as CFO exits, marking an upgrade from prior expectations
read at Endpoints ↗Neutral
Novo announced that its 2026 sales outlook will be flat, a shift from earlier growth expectations.
The drugmaker also disclosed that its chief financial officer will be leaving the company, and a transition plan is under way.
Analysts view the flat forecast as an improvement over prior guidance, reflecting Novo's position in the GLP-1 market.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novo forecasts flat 2026 sales as finance chief departs”
read at Endpoints ↗77 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that